A meeting of the National Drug Scheduling Advisory Committee (NDSAC) was held on September 15, 2024, with the following interim recommendation made:

• Nirsevimab be granted Schedule II status

Any objections to this interim recommendation must be received by the NAPRA office by end of day October 23, 2024. Questions or comments should be directed to the NDSAC Secretariat via email at ndsac@napra.ca.